Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...

A study found that around 4 months after vaccination, people who received the RSV vaccine had a 79% reduction in their risk ...

Robust immune responses were observed among healthy and high-risk younger adults who received the Ad26/protein RSV preF vaccine.

The stocks in the Hong Kong pharmaceutical sector have recently shown an upward trend. As global capital flows positively ...

RESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) ...

Local health boards invited adults aged 75–79, including those turning 75 before July 2025, to come forward for their free ...

Prior to vaccine availability, RSV was a significant cause of illness and hospitalization in older adults in the U.S., ...

Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for mRESVIA, indicated for active immunization for the prevention of ...

Unlike a vaccine, the immunization provides a ready-made supply of antibody protection to babies without triggering an immune system response. Protection against severe RSV infection begins ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Expect efforts to discredit ACIP by portraying medical and public health experience as bias rather than the result of decades of fact-based investigations.

Feb. 19, 2025 – A vaccine for pregnant women that protects babies from respiratory syncytial virus (RSV) appears safe, according to two new studies that give researchers hope for widespread ...